LifeMD (NASDAQ:LFMD) Given Buy Rating at BTIG Research

BTIG Research reaffirmed their buy rating on shares of LifeMD (NASDAQ:LFMD) in a research note published on Tuesday,Benzinga reports. They currently have a $10.00 price target on the stock.

A number of other brokerages have also recently commented on LFMD. B. Riley Financial reduced their price objective on LifeMD from $12.00 to $10.00 and set a “buy” rating on the stock in a research note on Tuesday, November 18th. Mizuho dropped their target price on LifeMD from $8.00 to $6.00 and set a “neutral” rating on the stock in a report on Wednesday, November 19th. HC Wainwright reduced their price target on LifeMD from $13.00 to $9.00 and set a “buy” rating on the stock in a research report on Wednesday, November 19th. Lake Street Capital decreased their price target on LifeMD from $14.00 to $8.00 and set a “buy” rating for the company in a report on Tuesday, November 18th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of LifeMD in a research report on Monday, December 29th. Six investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, LifeMD has an average rating of “Moderate Buy” and an average price target of $8.43.

LifeMD Trading Up 25.3%

Shares of LFMD stock opened at $3.91 on Tuesday. The company has a market cap of $188.23 million, a PE ratio of 15.04 and a beta of 1.92. The company’s fifty day simple moving average is $3.30 and its 200-day simple moving average is $4.56. LifeMD has a 52 week low of $2.56 and a 52 week high of $15.84.

LifeMD (NASDAQ:LFMD) last announced its quarterly earnings results on Monday, March 9th. The company reported ($0.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.03). LifeMD had a negative return on equity of 497.20% and a net margin of 6.58%.The business had revenue of $46.87 million for the quarter, compared to analysts’ expectations of $48.57 million. Equities research analysts expect that LifeMD will post -0.56 EPS for the current fiscal year.

Institutional Investors Weigh In On LifeMD

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Federated Hermes Inc. grew its position in shares of LifeMD by 278.1% during the fourth quarter. Federated Hermes Inc. now owns 980,285 shares of the company’s stock worth $3,343,000 after buying an additional 721,018 shares in the last quarter. Prescott Group Capital Management L.L.C. acquired a new position in LifeMD during the 4th quarter worth $2,344,000. Arrowstreet Capital Limited Partnership grew its holdings in LifeMD by 1,767.8% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 434,937 shares of the company’s stock worth $5,924,000 after acquiring an additional 411,651 shares in the last quarter. JPMorgan Chase & Co. increased its position in shares of LifeMD by 581.2% in the 2nd quarter. JPMorgan Chase & Co. now owns 412,571 shares of the company’s stock worth $5,619,000 after purchasing an additional 352,004 shares during the last quarter. Finally, Jump Financial LLC increased its position in shares of LifeMD by 205.0% in the 2nd quarter. Jump Financial LLC now owns 515,052 shares of the company’s stock worth $7,015,000 after purchasing an additional 346,171 shares during the last quarter. 35.52% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting LifeMD

Here are the key news stories impacting LifeMD this week:

• Positive Sentiment: Strong full‑year performance: 2025 revenue grew 25% to $194.1M and adjusted EBITDA rose 309% to $15.3M; cash of $36.8M and no debt provide runway for growth. Read More.
• Positive Sentiment: Weight‑management momentum: LifeMD launched oral Wegovy and reports >80% of new patients initiating branded therapy with record Q1 sign‑ups — a high‑margin growth driver tied to GLP‑1 adoption. Read More.
• Positive Sentiment: Analyst support: BTIG reaffirmed a “Buy” and set a $10 price target (material upside vs. current levels); several other firms have recently issued buy/overweight ratings, supporting sentiment. Read More.
• Positive Sentiment: Outlook implies meaningful growth: FY2026 revenue guidance of $220–$230M and adjusted EBITDA guidance of $12–$17M point to continued scale and margin improvement over the year. Read More.
• Neutral Sentiment: Call / transcript available — management hosted a conference call to walk through results and guidance; read the transcript for management color on GLP‑1 strategy and CAC assumptions. Read More.
• Negative Sentiment: Quarterly beat/miss nuance: LifeMD reported Q4 EPS of $(0.04) vs. consensus $(0.01) (a miss) and revenue of $46.87M vs. ~$48.57M consensus — a short‑term disappointment that can pressure sentiment. Read More.
• Negative Sentiment: Near‑term investment drag: Q1 2026 guidance calls for revenue of $48–$49M (below prior consensus) and an adjusted EBITDA loss of $4–$5M as the company front‑loads customer acquisition to scale GLP‑1 sign‑ups — implies short‑term margin pressure. Read More.
• Negative Sentiment: Legal and insider signals: Company disclosures note class‑action litigation; Quiver reports recent insider sales and mixed institutional flow (some large holders trimming positions), which can weigh on sentiment. Read More.

LifeMD Company Profile

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.